Subtype-selective targeting of voltage-gated sodium channels

British Journal of Pharmacology

Volumn 158, Issue 6, 2009, Pages 1413-1425

  England, Steve ^a   De Groot, Marcel J ^a  

^a PFIZER INC   (United States)

Author keywords

Local anaesthetic; Structural biology; Subtype selectivity; Toxin; Voltage gated sodium channel

Indexed keywords

VOLTAGE GATED SODIUM CHANNEL;

ATAXIA; CHANNELOPATHY; DRUG TARGETING; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGY; EPILEPSY; FAMILIAL HEMIPLEGIC MIGRAINE; GENE MUTATION; HEART ARRHYTHMIA; HUMAN; PAIN; PERIODIC PARALYSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ELECTROPHYSIOLOGY; HUMANS; SEQUENCE HOMOLOGY, AMINO ACID; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350547576     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00437.x     Document Type: Review

References (118)

1. Akhtar M, Goldschlager NF (2006). Brugada electrocardiographic pattern due to tricyclic antidepressant overdose. J Electrocardiol 39 : 336 339.
2. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J et al. (1999). The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 2 : 541 548.
3. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2 S1 S209.
4. Babb RR, Alarcon-Segovia D, Fairbairn JF 2nd. (1964). Erythermalgia. Review of 51 cases. Circulation 29 : 136 141.
5. Bolognesi R, Tsialtas D, Vasini P, Conti M, Manca C (1997). Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am J Cardiol 79 : 242 245.
6. Borchard U, Bösken R, Greeff K (1982). Characterization of antiarrhythmic drugs by alternating current induced arrhythmias in isolated heart tissues. Arch Int Pharmacodyn Ther 256 : 253 268.
7. Bosmans F, Rash L, Zhu S, Diochot S, Lazdunski M, Escoubas P et al. (2006). Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes. Mol Pharmacol 69 : 419 429.
8. Brown GB (1986). 3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin. J Neurosci 6 : 2064 2070.
9. Browne LE, Blaney FE, Yusaf SP, Clare JJ, Wray D (2009). Structural determinants of drugs acting on the nav1.8 channel. J Biol Chem 284 : 10523 10536.
10. Cannon SC (2000). Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses. Kidney Int 57 : 772 779.
11. Castro MJ, Stam AH, Lemos C, de Vries B, Vanmolkot KR, Barros J et al. (2009). First mutation in the voltage-gated Nav1.1 subunit gene SCN1A with co-occurring familial hemiplegic migraine and epilepsy. Cephalalgia 29 : 308 313.
12. Catterall WA, Goldin AL, Waxman SG (2005). International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57 : 397 409.
13. Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D (2008). Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci 28 : 11768 11777.
14. Chahine M, Sirois J, Marcotte P, Chen L, Kallen RG (1998). Extrapore residues of the S5-S6 loop of domain 2 of the voltage-gated skeletal muscle sodium channel (rSkM1) contribute to the mu-conotoxin GIIIA binding site. Biophys J 75 : 236 246.
15. Cheng X, Dib-Hajj SD, Tyrrell L, Waxman SG (2008). Mutation I136V alters electrophysiological properties of the Na(v)1.7 channel in a family with onset of erythromelalgia in the second decade. Mol Pain 4 : 1.
16. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS et al. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318 : 1258 1265.
17. Chernoff DM (1990). Kinetic analysis of phasic inhibition of neuronal sodium currents by lidocaine and bupivacaine. Biophys J 58 : 53 68.
18. Chernoff DM, Strichartz GR (1990). Kinetics of local anesthetic inhibition of neuronal sodium currents. pH and hydrophobicity dependence. Biophys J 58 : 69 81.
19. Choudhary G, Aliste MP, Tieleman DP, French RJ, Dudley SC Jr. (2007). Docking of mu-conotoxin GIIIA in the sodium channel outer vestibule. Channels (Austin) 1 : 344 352.
20. Courtney KR, Kendig JJ, Cohen EN (1978). The rates of interaction of local anesthetics with sodium channels in nerve. J Pharmacol Exp Ther 207 : 594 604.
21. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K et al. (2006). An SCN9A channelopathy causes congenital inability to experience pain. Nature 444 : 894 898.
22. Cronin NB, O'Reilly A, Duclohier H, Wallace BA (2003). Binding of the anticonvulsant drug lamotrigine and the neurotoxin batrachotoxin to voltage-gated sodium channels induces conformational changes associated with block and steady-state activation. J Biol Chem 278 : 10675 10682.
23. Cummins TR, Aglieco F, Dib-Hajj SD (2002). Critical molecular determinants of voltage-gated sodium channel sensitivity to mu-conotoxins GIIIA/B. Mol Pharmacol 61 : 1192 1201.
24. Cummins TR, Dib-Hajj SD, Waxman SG (2004). Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci 24 : 8232 8236.
25. Cusdin FS, Clare JJ, Jackson AP (2008). Trafficking and cellular distribution of voltage-gated sodium channels. Traffic 9 : 17 26.
26. De Curtis M, Avanzini G (2001). Interictal spikes in focal epileptogenesis. Prog Neurobiol 63 (5 541 567.
27. Dearborn GVN (1932). A case of congenital pure analgesia. Nerv Ment Dis 75 : 612 615.
28. Dib-Hajj SD, Fjell J, Cummins TR, Zheng Z, Fried K, LaMotte R et al. (1999). Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 83 : 591 600.
29. Dib-Hajj SD, Binshtok AM, Cummins TR, Jarvis MF, Samad T, Zimmermann K (2009). Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res Rev 60 : 65 83.
30. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT (2007). Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain 8 : 315 324.
31. Drenth JP, Michiels JJ (1992). Clinical characteristics and pathophysiology of erythromelalgia and erythermalgia. Am J Med 93 : 111 114.
32. Drenth JP, Te Morsche RH, Mansour S, Mortimer PS (2008). Primary erythermalgia as a sodium channelopathy: screening for SCN9A mutations: exclusion of a causal role of SCN10A and SCN11A. Arch Dermatol 144 : 320 324.
33. Drizin I, Gregg RJ, Scanio MJ, Shi L, Gross MF, Atkinson RN et al. (2008). Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem 16 : 6379 6386.
34. Du Y, Lee JE, Nomura Y, Zhang T, Zhorov BS, Dong K (2009). Identification of a cluster of residues in transmembrane segment 6 of domain III of the cockroach sodium channel essential for the action of pyrethroid insecticides. Biochem J 419 : 377 385.
35. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 : 781 788.
36. Ekberg J, Jayamanne A, Vaughan CW, Aslan S, Thomas L, Mould J et al. (2006). muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci USA 103 : 17030 17035.
37. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B et al. (2006). SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52 : 767 774.
38. Fertleman CR, Ferrie CD, Aicardi J, Bednarek NA, Eeg-Olofsson O, Elmslie FV et al. (2007). Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). Neurology 69 : 586 595.
39. Fiedler B, Zhang MM, Buczek O, Azam L, Bulaj G, Norton RS et al. (2008). Specificity, affinity and efficacy of iota-conotoxin RXIA, an agonist of voltage-gated sodium channels Na(V)1.2, 1.6 and 1.7. Biochem Pharmacol 75 : 2334 2344.
40. Ford FR, Wilkins L (1938). Congenital universal insensitiveness to pain. A clinical report of three cases in children with discussion of the literature. Bull Johns Hopkins Hosp 62 : 448 446.
41. Fozzard HA, Lee PJ, Lipkind GM (2005). Mechanism of local anesthetic drug action on voltage-gated sodium channels. Curr Pharm Des 11 : 2671 2686.
42. Fujiwara T, Sugawara T, Mazaki-Miyazaki E, Takahashi Y, Fukushima K, Watanabe M et al. (2003). Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 126 : 531 546.
43. Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M et al. (2007). Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 71 : 311 319.
44. Goldgran-Toledano D, Sideris G, Kevorkian JP (2002). Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 346 : 1591 1592.
45. Han C, Dib-Hajj SD, Lin Z, Li Y, Eastman EM, Tyrrell L et al. (2009). Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation. Brain 132 : 1711 1722.
46. Harris A, Goldberg LG (1931). Spinal anesthesia with nupercaine and procaine: a comparative study. Ann Surg 94 : 934 938.
47. Hemming K, Maguire MJ, Hutton JL, Marson AG (2008). Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev 3 : CD007302. DOI: 10.1002/14651858.CD007302.
48. Hille B (1977). Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 69 : 497 515.
49. Hille B (1992). Ionic Channels of Excitable Membranes, 2nd edn. Sinauer Associates : Sunderland, Masachusetts.
50. Hirsch E, Moye D, Dimon JH 3rd. (1995). Congenital indifference to pain: long-term follow-up of two cases. South Med J 88 : 851 857.
51. Isom LL, Catterall WA (1996). Na+ channel subunits and Ig domains. Nature 383 : 307 308.
52. Jarecki BW, Sheets PL, Jackson JO 2nd., Cummins TR (2008). Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation. J Physiol 586 : 4137 4153.
53. Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF et al. (2007). A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 104 : 8520 8525.
54. Keynes RD, Rojas E (1974). Kinetics and steady-state properties of the charged system controlling sodium conductance in the squid giant axon. J Physiol 239 : 393 434.
55. Khoo KK, Feng ZP, Smith BJ, Zhang MM, Yoshikami D, Olivera BM et al. (2009). Structure of the analgesic mu-conotoxin KIIIA and effects on the structure and function of disulfide deletion. Biochemistry 48 : 1210 1219.
56. Kola I, Landis J (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Disc 3 : 711 715.
57. Kort ME, Drizin I, Gregg RJ, Scanio MJ, Shi L, Gross MF et al. (2008). Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J Med Chem 51 : 407 416.
58. Kuo CC, Lu L (1997). Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Br J Pharmacol 121 : 1231 1238.
59. Lai HC, Jan LY (2006). The distribution and targeting of neuronal voltage-gated ion channels. Nat Rev Neurosci 7 : 548 562.
60. Lai J, Hunter JC, Ossipov MH, Porreca F (2000). Blockade of neuropathic pain by antisense targeting of tetrodotoxin-resistant sodium channels in sensory neurons. Methods Enzymol 314 : 201 213.
61. Lewis RJ, Schroeder CI, Ekberg J, Nielsen KJ, Loughnan M, Thomas L et al. (2007). Isolation and structure-activity of mu-conotoxin TIIIA, a potent inhibitor of tetrodotoxin-sensitive voltage-gated sodium channels. Mol Pharmacol 71 : 676 685.
62. Liao Z, Yuan C, Deng M, Li J, Chen J, Yang Y et al. (2006). Solution structure and functional characterization of jingzhaotoxin-XI: a novel gating modifier of both potassium and sodium channels. Biochemistry 45 : 15591 15600.
63. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23 : 3 25.
64. Lipkind GM, Fozzard HA (1994). A structural model of the tetrodotoxin and saxitoxin binding site of the Na+ channel. Biophys J 66 : 1 13.
65. Lipkind GM, Fozzard HA (2005). Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol 68 : 1611 1622.
66. London C, Hoyt SB, Parsons WH, Williams BS, Warren VA, Tschirret-Guth R et al. (2008). Imidazopyridines: a novel class of hNav1.7 channel blockers. Bioorg Med Chem Lett 18 : 1696 1701.
67. Long SB, Campbell EB, Mackinnon R (2005). Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 309 : 897 903.
68. Long SB, Tao X, Campbell EB, MacKinnon R (2007). Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment. Nature 450 : 376 382.
69. Losa M, Scheier H, Rohner P, Sailer H, Hayek J, Giedion A et al. (1989). Long-term course in congenital analgesia. Schweiz Med Wochenschr 119 : 1303 1308.
70. Lossin C, Rhodes TH, Desai RR, Vanoye CG, Wang D, Carniciu S et al. (2003). Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci 23 : 11289 11295.
71. Matthews PB, Rushworth G (1957). The relative sensitivity of muscle nerve fibres to procaine. J Physiol 135 : 263 269.
72. Meisler MH, Kearney JA (2005). Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 115 : 2010 2017.
73. Misra SN, Kahlig KM, George AL Jr. (2008). Impaired NaV1.2 function and reduced cell surface expression in benign familial neonatal-infantile seizures. Epilepsia 49 : 1535 1545.
74. Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA (2005). SCN1A mutations and epilepsy. Hum Mutat 25 : 535 542.
75. Nagasako EM, Oaklander AL, Dworkin RH (2003). Congenital insensitivity to pain: an update. Pain 101 : 213 219.
76. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J et al. (2005). Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 294 : 2975 2980.
77. Narahashi T (2008). Tetrodotoxin: a brief history. Proc Jpn Acad Ser B Phys Biol Sci 84 : 147 154.
78. Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA, Dickenson AH et al. (2004). Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA 101 : 12706 12711.
79. Nassar MA, Levato A, Stirling LC, Wood JN (2005). Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Mol Pain 1 : 24.
80. Nassar MA, Baker MD, Levato A, Ingram R, Mallucci G, McMahon SB et al. (2006). Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol Pain 2 : 33.
81. Nau C, Wang GK (2004). Interactions of local anesthetics with voltage-gated Na+ channels. J Membr Biol 201 : 1 8.
82. Nicholson GM (2007). Insect-selective spider toxins targeting voltage-gated sodium channels. Toxicon 49 : 490 512.
83. Noda M, Ikeda T, Suzuki H, Takeshima H, Takahashi T, Kuno M et al. (1986). Expression of functional sodium channels from cloned cDNA. Nature 322 : 826 828.
84. Nurani G, Radford M, Charalambous K, O'Reilly AO, Cronin NB, Haque S et al. (2008). Tetrameric bacterial sodium channels: characterization of structure, stability, and drug binding. Biochemistry 47 : 8114 8121.
85. Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I et al. (2007). Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Sc1a gene mutation. J Neurosci 27 : 5903 5914.
86. Piredda S, Yonekawa W, Whittingham TS, Kupferberg HJ (1986). Effects of antiepileptic drugs on pentylenetetrazole-induced epileptiform activity in the in vitro hippocampus. Epilepsia 27 : 341 346.
87. Porto GG, Vasconcelos BC, Gomes AC, Albert D (2007). Evaluation of lidocaine and mepivacaine for inferior third molar surgery. Med Oral Patol Oral Cir Bucal 12 : E60 E64
88. Postma SW, Catterall WA (1984). Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by local anesthetics. Mol Pharmacol 25 : 219 227.
89. Priest BT, Murphy BA, Lindia JA, Diaz C, Abbadie C, Ritter AM et al. (2005). Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci U S A 102 : 9382 9387.
90. Ragsdale DS (2008). How do mutant Nav1.1 sodium channels cause epilepsy? Brain Res Rev 58 : 149 159.
91. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA (1994). Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 265 : 1724 1728.
92. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA (1996). Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc Natl Acad Sci USA 93 : 9270 9275.
93. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC et al. (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450 : 383 387.
94. Ren D, Navarro B, Xu H, Yue L, Shi Q, Clapham DE (2001). A prokaryotic voltage-gated sodium channel. Science 294 : 2372 2375.
95. Rosker C, Lohberger B, Hofer D, Steinecker B, Quasthoff S, Schreibmayer W (2007). The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium channel. Am J Physiol Cell Physiol 293 : C783 C789.
96. Rouleau F, Asfar P, Boulet S, Dube L, Dupuis JM, Alquier P et al. (2001). Transient ST-segment elevation in right precordial leads induced by psychotropic drugs: relationship to Brugada syndrome. J Cardiovasc Electrophysiol 12 : 61 65.
97. Sato C, Ueno Y, Asai K, Takahashi K, Sato M, Engel A et al. (2001). The voltage-sensitive sodium channel is a bell-shaped molecule with several cavities. Nature 409 : 1047 1051.
98. Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG, Weinglass AB et al. (2008). ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol 74 : 1476 1484.
99. Schubert R, Cracco JB (1992). Familial rectal pain: a type of reflex epilepsy? Ann Neurol 32 : 824 826.
100. Schulze-Bahr E, Eckardt L, Breithardt G, Seidl K, Wichter T, Wolpert C et al. (2003). Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat 21 : 651 652.
101. Shafrir Y, Durell SR, Guy HR (2008a). Models of the structure and gating mechanisms of the pore domain of the NaChBac ion channel. Biophys J 95 : 3650 3662.
102. Shafrir Y, Durell SR, Guy HR (2008b). Models of voltage-dependent conformational changes in NaChBac channels. Biophys J 95 : 3663 3676.
103. Sharkey LM, Cheng X, Drews V, Buchner DA, Jones JM, Justice MJ et al. (2009). The ataxia3 mutation in the N-terminal cytoplasmic domain of sodium channel Na(v)1.6 disrupts intracellular trafficking. J Neurosci 29 : 2733 2741.
104. Tan HL, Bezzina CR, Smits JP, Verkerk AO, Wilde AA (2003). Genetic control of sodium channel function. Cardiovasc Res 57 : 961 973.
105. Trudeau MM, Dalton JC, Day JW, Ranum LP, Meisler MH (2006). Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J Med Genet 43 : 527 530.
106. Tseng TT, McMahon AM, Johnson VT, Mangubat EZ, Zahm RJ, Pacold ME et al. (2007). Sodium channel auxiliary subunits. J Mol Microbiol Biotechnol 12 : 249 262.
107. Van Wart A, Trimmer JS, Matthews G (2007). Polarized distribution of ion channels within microdomains of the axon initial segment. J Comp Neurol 500 : 339 352.
108. Vega AV, Henry DL, Matthews G (2008). Reduced expression of Na(v)1.6 sodium channels and compensation by Na(v)1.2 channels in mice heterozygous for a null mutation in Scn8a. Neurosci Lett 442 : 69 73.
109. Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ et al. (2006). The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 129 : 8 17.
110. Wallace RH, Wang DW, Singh R, Scheffer IE, George AL Jr., Phillips HA et al. (1998). Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat Genet 19 : 366 370.
111. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R et al. (2008). Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454 (7203 486 491.
112. Waxman SG, Kocsis JD, Black JA (1994). Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol 72 : 466 470.
113. Williams BS, Felix JP, Priest BT, Brochu RM, Dai K, Hoyt SB et al. (2007). Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry 46 : 14693 14703.
114. Willow M, Catterall WA (1982). Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 22 : 627 635.
115. Xiao Y, Bingham JP, Zhu W, Moczydlowski E, Liang S, Cummins TR (2008). Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain II voltage sensor in the closed configuration. J Biol Chem 283 : 27300 27313.
116. Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA et al. (2006). Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9 : 1142 1149.
117. Zhao Y, Yarov-Yarovoy V, Scheuer T, Catterall WA (2004). A gating hinge in Na+ channels; a molecular switch for electrical signaling. Neuron 41 : 859 865.
118. Zimmer T, Surber R (2008). SCN5A channelopathies- An update on mutations and mechanisms. Prog Biophys Mol Biol 98 : 120 136.